Chromatin remodeling refers to the dynamic modifications of chromatin structure that regulate gene expression patterns. These epigenetic mechanisms play crucial roles in neuronal development, synaptic plasticity, learning and memory, and are increasingly recognized as important factors in neurodegenerative disease pathogenesis. This page provides comprehensive information about chromatin biology and its dysregulation in Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, and other neurodegenerative conditions.
Chromatin remodeling encompasses:
- Covalent histone modifications: Acetylation, methylation, phosphorylation, ubiquitination
- ATP-dependent chromatin remodeling: SWI/SNF, ISWI, CHD, INO80 complexes
- DNA methylation: 5-methylcytosine, 5-hydroxymethylcytosine
- Non-coding RNA regulation: miRNAs, lncRNAs, piRNAs
These mechanisms collectively regulate transcription factor access to DNA, controlling which genes are expressed in different neuronal cell types and under different conditions.
The nucleosome### Nucleosome Composition is the basic unit of chromatin:
- DNA (∼147 bp) wrapped around histone octamer
- Histone H2A, H2B, H3, H4 (two copies each)
- Histone H1 linker protein
- Histone tails subject to post-translational modifications
Chromatin exists in multiple states:
- Euchromatin: Open, transcriptionally active
- Heterochromatin: Condensed, silent (facultative or constitutive)
- Nuclear architecture: Lamina-associated domains, topologically associating domains
Acetylation
- Neutralizes positive lysine charge
- Reduces histone-DNA interaction
- Opens chromatin for transcription
- Key marks: H3K9ac, H3K27ac, H4K16ac
Methylation
- Can activate or repress depending on site
- H3K4me3: Active promoters
- H3K27me3: Polycomb repression
- H3K9me3: HP1-mediated silencing
Phosphorylation
- Often marks DNA damage response
- H2A.X phosphorylation (γH2AX) at DSBs
- H3S10 phosphorylation in mitosis
Ubiquitination
- H2A/H2A.Z ubiquitination in gene regulation
- Histone turnover
5-methylcytosine (5mC)
- CpG dinucleotide methylation
- Gene silencing through methyl-binding proteins
- Imprinting, X-inactivation
5-hydroxymethylcytosine (5hmC)
- Intermediate in demethylation
- Enriched in brain
- Distinct regulatory functions
- miRNAs: Post-transcriptional regulation
- lncRNAs: Scaffold for chromatin modifiers
- piRNAs: Genome defense in germline
SWI/SNF (BAF) Complexes
- 15 subunits in mammals
- Variable subunit composition defines function
- Neuron-specific BAF53a, BAF53b, BAF45
- Mutations in neurodevelopmental disorders
ISWI Complexes
- Nucleosome spacing
- Chromatin assembly
- Cognitive function regulation
CHD (Chromodomain Helicase DNA-binding)
- Chromatin organization
- Neuronal gene expression
INO80 Complex
- DNA repair
- Transcription regulation
Histone Acetyltransferases (HATs)
- p300/CBP: Transcriptional coactivators
- PCAF, GCN5: H3K9ac, H3K27ac
- CREB-binding protein functions
Histone Deacetylases (HDACs)
- Class I (HDAC1,2,3,8): Nuclear
- Class II (HDAC4-7,9,10): Tissue-specific
- Class III (Sirtuins): NAD⁺-dependent
- Class IV (HDAC11): Brain-enriched
Histone Methyltransferases (HMTs)
- SET-domain proteins
- SUV39H1, G9a, EZH2
- Non-SET domain methyltransferases
Histone Demethylases (HDMs)
- LSD1 (KDM1A): H3K4/K9 demethylation
- JmjC-domain proteins: KDM2-7 family
Histone Modification Changes
- Reduced H3K9ac at synaptic plasticity genes
- Increased H3K27me3 repressive marks
- HDAC2 overexpression impairs memory
- HDAC inhibitor benefits in models
DNA Methylation
- Global hypomethylation in AD brain
- Specific gene hypermethylation
- EPHA2, SOCKS3A demethylation
- 5hmC alterations
Therapeutic Implications
- HDAC inhibitors enhance cognition
- p300/CBP inhibitors in trials
- Epigenetic therapy combinations
α-Synuclein-Chromatin Interactions
- α-Synuclein localizes to nucleus
- May affect histone acetylation
- Interacts with PARP1
DNA Methylation
- PARK16, SLC2A13 methylation changes
- Global methylation alterations
- SNCA promoter methylation variable
Histone Modifications
- HDAC inhibition protects dopaminergic neurons
- H3K9me3 alterations
- SIRT1 activity changes
Transcription Dysregulation
- P300/CBP recruitment defects
- Repressive complex recruitment
- Polyglutamine effects on chromatin
HDAC Inhibitor Therapy
- Sodium butyrate, valproic acid effects
- Vorinostat in trials
- HDAC4/5 alterations
Therapeutic Targets
- Class I HDAC inhibitors
- HMT inhibitors
- Bromodomain inhibitors
TDP-43 Pathology
- TDP-43 sequesters histone mRNAs
- Affects chromatin assembly
- Nucleocytoplasmic transport defects
C9orf72 Repeats
- RNA foci affect splicing
- Dipeptide repeats impact nuclear functions
- Epigenetic dysregulation
HDAC Changes
- HDAC6 in autophagy
- Class IIa alterations
- Therapeutic targeting
Class I Selective
- Vorinostat (SAHA): Approved, trials in HD
- Romidepsin: Class I selective
- Entinostat (MS-275): Brain-penetrant
Class IIa Selective
- Valproic acid: Mood stabilizer, HD trials
- Sodium butyrate: Preclinical
Pan-HDAC Inhibitors
- Vorinostat: Phase trials
- Panobinostat: Potent, brain penetration
¶ Bromodomain Inhibitors
- JQ1: BET protein inhibitor
- I-BET151: Neuroprotective in models
- OTX015: Clinical trials
- EZH2 inhibitors: DOT1L inhibitors
- PRMT5 inhibitors: In development
- LSD1 inhibitors: Neuroprotective
- Azacitidine: DNMT inhibitor
- Decitabine: FDA-approved
- TET inhibitors: Emerging
Histone Modifications
- H3K9ac in blood/CSF
- H3K27me3 signatures
- Global histone acetylation
DNA Methylation
- Blood-based methylation signatures
- 5hmC as neuronal marker
- Epigenetic clocks
- HDAC gene mutations
- SWI/SNF complex mutations
- Epigenetic regulator variants
- HDAC activity levels
- 5mC/5hmC reader proteins
- Chromatin remodeler levels
The study of Chromatin Remodeling In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Coppedè F, et al. DNA methylation in Alzheimer's disease: The role of epigenetics. J Neurol Sci. 2024
- Graff J, et al. An epigenetic blockade to cognitive function: HDAC2 and synaptic plasticity. Nat Neurosci. 2012
- Kandemir H, et al. Histone modifications in Parkinson's disease. Nat Rev Neurosci. 2023
- Valor LM, et al. Epigenetic basis of Huntington's disease. J Huntington Dis. 2022
- Chen X, et al. Chromatin remodeling in ALS/FTD. Acta Neuropathol. 2024
- Kazantsev AG, et al. Therapeutic targeting of epigenetic dysregulation. Nat Rev Drug Discov. 2022
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
6 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 26%